WO2004005930A3 - Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases - Google Patents
Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases Download PDFInfo
- Publication number
- WO2004005930A3 WO2004005930A3 PCT/DE2003/002288 DE0302288W WO2004005930A3 WO 2004005930 A3 WO2004005930 A3 WO 2004005930A3 DE 0302288 W DE0302288 W DE 0302288W WO 2004005930 A3 WO2004005930 A3 WO 2004005930A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- neurodegenerative diseases
- diagnosis
- human
- pharmaceutical substances
- diseases
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the use of known pharmaceutical substances chloropromazine, ethacrine, quinacrine, lovastatine, doxorubicine and D-penicillamine for the diagnosis of human and animal neurodegenerative diseases such prion diseases as TSE diseases suc has BSE, CJD, vCJD, scrapie and other neurodegenerative diseases based on the formation of neurotoxic amyloid plaques. Body fluids such as whole blood, plasma, serum, liquor, urine, milk, lymph, lymph plasma and saliva, i.e. body fluids containing proteins, are used as test media. Previously, said substances were used therapeutically as psychopharmaceuticals, cycostatics, lipid reducres, antirheumatics and antiparasite agents. The invention also relates to a method for the diagnosis of human and animal neurodegenerative diseases, wherein said pharmaceutical substances are used.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003247252A AU2003247252A1 (en) | 2002-07-04 | 2003-07-03 | Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10230838.1 | 2002-07-04 | ||
DE2002130838 DE10230838B4 (en) | 2002-07-04 | 2002-07-04 | Diagnostic use of pharmaceutical substances |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004005930A2 WO2004005930A2 (en) | 2004-01-15 |
WO2004005930A3 true WO2004005930A3 (en) | 2004-03-18 |
Family
ID=29761777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2003/002288 WO2004005930A2 (en) | 2002-07-04 | 2003-07-03 | Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003247252A1 (en) |
DE (1) | DE10230838B4 (en) |
WO (1) | WO2004005930A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103172604B (en) * | 2011-12-22 | 2015-06-24 | 北大方正集团有限公司 | Lovastatin purification method combining auxiliary magnetic crystallization |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981208A (en) * | 1992-04-09 | 1999-11-09 | Bayer Corporation | Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein |
DE10130727A1 (en) * | 2001-06-21 | 2003-01-09 | Mediquant Gmbh | Method and device for measuring micro-viscosity changes as an immunoassay |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9908059D0 (en) * | 1999-04-09 | 1999-06-02 | Imp College Innovations Ltd | Diagnosis and treatment of diseases |
US6589504B1 (en) * | 2000-09-22 | 2003-07-08 | Pharmacia & Upjohn Company | Compounds and methods for diagnosing and treating amyloid-related conditions |
-
2002
- 2002-07-04 DE DE2002130838 patent/DE10230838B4/en not_active Expired - Fee Related
-
2003
- 2003-07-03 AU AU2003247252A patent/AU2003247252A1/en not_active Abandoned
- 2003-07-03 WO PCT/DE2003/002288 patent/WO2004005930A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981208A (en) * | 1992-04-09 | 1999-11-09 | Bayer Corporation | Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein |
DE10130727A1 (en) * | 2001-06-21 | 2003-01-09 | Mediquant Gmbh | Method and device for measuring micro-viscosity changes as an immunoassay |
Non-Patent Citations (3)
Title |
---|
BORANIC M ET AL: "A PARKINSON-LIKE SYNDROME AS SIDE EFFECT OF CHEMO THERAPY WITH VINCRISTINE AND ADRIAMYCIN IN A CHILD WITH ACUTE LEUKEMIA", BIOMEDICINE EXPRESS (PARIS), vol. 31, no. 5, 1979, pages 124 - 125, XP009019730, ISSN: 0300-0885 * |
PAHAN K ET AL: "LOVASTATIN AND PHENYLACETATE INHIBIT THE INDUCTION OF NITRIC OXIDE SYNTHASE AND CYTOKINES IN RAT PRIMARY ASTROCYTES, MICROGLIA, AND MACROPHAGES", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 100, no. 11, December 1997 (1997-12-01), pages 2671 - 2679, XP002917163, ISSN: 0021-9738 * |
PETERS L ET AL: "D-Penicillamine metabolism in neurodegenerative diseases: An in vivo/in vitro sulphydryl methylation study", XENOBIOTICA 1994 UNITED KINGDOM, vol. 24, no. 10, 1994, pages 1013 - 1020, XP009019643, ISSN: 0049-8254 * |
Also Published As
Publication number | Publication date |
---|---|
DE10230838A9 (en) | 2004-09-09 |
DE10230838B4 (en) | 2005-02-03 |
WO2004005930A2 (en) | 2004-01-15 |
AU2003247252A1 (en) | 2004-01-23 |
DE10230838A1 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bittar et al. | Advances and considerations in AD tau-targeted immunotherapy | |
Walsh et al. | The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain | |
Park et al. | Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice | |
Qing et al. | Degradation of BACE by the ubiquitin‐proteasome pathway | |
Sennvik et al. | Levels of α-and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients | |
Chyung et al. | Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid β-protein at the cell surface | |
Maruyama et al. | Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease | |
Chintamaneni et al. | Biomarkers in Alzheimer's disease: a review | |
Ray et al. | Biochemical studies in normal pressure hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau | |
Lai et al. | Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease | |
Ghanevati et al. | Phospho-β-catenin accumulation in Alzheimer’s disease and in aggresomes attributable to proteasome dysfunction | |
Mamada et al. | Amyloid β-protein oligomers upregulate the β-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons | |
van Weering et al. | Endolysosome and autolysosome dysfunction in Alzheimer’s disease: where intracellular and extracellular meet | |
de Almeida et al. | Opposing effects of cucurbit [7] uril and 1, 2, 3, 4, 6-penta-O-galloyl-β-d-glucopyranose on amyloid β25–35 assembly | |
Lin et al. | Region-specific expression of tau, amyloid-β protein precursor, and synaptic proteins at physiological condition or under endoplasmic reticulum stress in rats | |
Nagamine et al. | Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains | |
WO2009100953A3 (en) | Diagnostic method | |
Lagalwar et al. | Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer’s disease and tauopathies to granulovacuolar degeneration bodies | |
US20200132683A1 (en) | Rapid multiplex diagnostic for parkinson's disease and alzheimer's disease | |
Nutu et al. | Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases | |
WO2004005930A3 (en) | Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases | |
Zetterberg et al. | Cerebrospinal fluid analysis should be considered in patients with cognitive problems | |
JP5677297B2 (en) | Glutaminyl cyclase as an indicator for diagnosis / prognosis of neurodegenerative diseases | |
Winkler et al. | Rapid cerebral amyloid binding by Aβ antibodies infused into β-amyloid precursor protein transgenic mice | |
R Sadleir et al. | Elevated Aβ42 in aged, non-demented individuals with cerebral atherosclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AU BA BG BR CA CN CO CR CU CZ DM DZ EC EE HR HU ID IL IN IS JP KP KR LK LR LT LV MA MD MK MN MX NO NZ PL RO SG SK TR TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |